Clinical Trial Results: Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab combined with chemotherapy and investigational agents as first-line treatment for extensive-stage small cell lung cancer;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Investigational agents
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2026-07-01